FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for SEROQUEL XR (quetiapine) by AstraZeneca Pharmaceuticals LP to update or expand the labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder
• Schizophrenia

Drugs mentioned

• SEROQUEL XR (Quetiapine)

Snippet

SUPPL AP for SEROQUEL XR (QUETIAPINE)